SOL-257 gene therapy improves outcomes in 2 ALS mouse models.
Researchers have reported encouraging results from preclinical
SOLA Biosciences Presents Preclinical Proof-of-Concept Data for SOL-257, a Gene Therapy Targeting Misfolded TDP-43 in ALS, at Neuroscience 2023 and ALS One Symposium.
SOLA Biosciences has shared new preclinical proof-of-concept
SOLA Biosciences Shares Preclinical Proof-of-Concept Data for SOL-257, a Gene Therapy Targeting Misfolded TDP-43 in ALS at 22nd Annual NEALS Meeting.
SOLA Biosciences has announced new preclinical proof-of-concept
Series Pre-A+ Financing completed with UTEC
Series Pre-A+ Financing completed with UTEC
SOLA presented in ALS ONE Conference
SOLA presented in ALS ONE Conference